Kerry Wentworth Buys Shares of NUVB $NUVB
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Kerry Wentworth, CHIEF REGULATORY OFFICER at Nuvation Bio Inc. ($NUVB), bought 63,000 shares at an average price of $2.93, for a total transaction of $184,590. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
Nuvation Bio Inc. Stock Down 3.0%
Shares of Nuvation Bio Inc. ($NUVB) traded around $6.46 on Thursday, down 3.0% for the day.
Nuvation Bio Inc. Earnings
Analysts Set New Price Targets
About Nuvation Bio Inc.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
Get Nuvation Bio Inc. alerts
New 13F filings, insider trades, and analyst moves on $NUVB, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.